Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts

ClinicalTrials.gov ID: NCT00499967

Public ClinicalTrials.gov record NCT00499967. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 6, 2026, 3:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Assessment of the Safety, Tolerability, and Activity of GS-9191 Ointment for the Treatment of External Genital and Perianal Warts Caused by Human Papilloma Virus Infection

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess the safety, tolerability and activity of GS-9191 ointment in the treatment of genital warts. GS-9191 ointment is intended for topical application directly to genital warts on the skin.

Study identification

NCT ID: NCT00499967
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Gilead Sciences; Industry
Enrollment: 202 participants

Conditions and interventions

Conditions

Genital Warts

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 50 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 31, 2007
Primary completion: Jan 31, 2009
Completion: Feb 28, 2009
Last update posted: Apr 8, 2009

2007 – 2009

United States locations

U.S. sites: 25
U.S. states: 15
U.S. cities: 23

Facility	City	State	ZIP	Site status
Not listed	Tucson	Arizona	85710	—
Not listed	Beverly Hills	California	90211	—
Not listed	Mission Viejo	California	92691	—
Not listed	San Francisco	California	94114	—
Not listed	San Francisco	California	94115	—
Not listed	Santa Rosa	California	95405	—
Not listed	Vallejo	California	94589	—
Not listed	Orlando	Florida	32803	—
Not listed	Tampa	Florida	33607	—
Not listed	Indianapolis	Indiana	46202	—
Not listed	St Louis	Missouri	63117	—
Not listed	Las Vegas	Nevada	89106	—
Not listed	New York	New York	10016	—
Not listed	Stony Brook	New York	11794	—
Not listed	Raleigh	North Carolina	27612	—
Not listed	Tulsa	Oklahoma	74105	—
Not listed	Portland	Oregon	97239	—
Not listed	Greenville	South Carolina	29605	—
Not listed	Chattanooga	Tennessee	37404	—
Not listed	Dallas	Texas	75231	—
Not listed	Houston	Texas	77058	—
Not listed	San Antonio	Texas	78217	—
Not listed	San Antonio	Texas	78229	—
Not listed	Salt Lake City	Utah	84132	—
Not listed	Seattle	Washington	98101	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00499967, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 8, 2009 · Synced Sep 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00499967 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →